UNSPSC 51334302: Clopenthixol

This classification denotes a dopamine antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0A432D932A. European Medicines Agency schedules Clopenthixol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06736MIG. Clopenthixol generally arises in the molecular formula C22H25CLN2OS.

The term CLOPENTHIXOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, list 5.) CLOPENTHIXOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule clopenthixol under HS 29349990 and SITC 51579. As of Q4 2014, CLOPENTHIXOL remains the US FDA Preferred Term for this commodity. SMILES: C1CN(CCN1CCC=C2C3=CC=CC=C3SC4=C2C=C(C=C4)CL)CCO.

UNSPSC 51334302 Clopenthixol is a Commodity code that nominally refers to a single antipsychotic pharmaceutical agent, but recent state and local solicitation activity shows minimal direct alignment with this specific drug. Instead, the code appears in procurement records tagged to broader pharmaceutical procurement initiatives—generic multi-source drugs, naloxone distribution systems, and pharmacy benefit program management—where clopenthixol may be one of many therapeutic agents under consideration rather than a primary focus. State and local governments buying under or near this code are acquiring pharmaceutical products through cooperative purchasing alliances, county health departments, and state health and human services commissions. The issuing bodies include the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration; Seminole County, Florida; and the Texas Health and Human Services Commission. These entities are conducting either formal competitive solicitations for pharmaceutical supply contracts or preliminary market-intelligence gathering to design future pharmacy benefit programs.

Recent activity is concentrated in the Upper Midwest and South. The Minnesota Department of Administration's MMCAP issued a Request for Proposal (RFP) posted January 20, 2026, with a due date of March 26, 2026, seeking generic multi-source pharmaceuticals and over-the-counter products for distribution across participating state and local government facilities in Minnesota and Oregon, with pricing weighted at 75 percent and contract effectiveness set for July 1, 2026. Seminole County, Florida posted an Invitation for Bid (IFB) on June 30, 2026, due July 26, 2023, for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building. The Texas Health and Human Services Commission issued a Request for Information (RFI) on April 3, 2026, to gather vendor capabilities regarding direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements. The code shows limited recent procurement volume and inconsistent tagging—a signal that clopenthixol procurement as a standalone pharmaceutical is not a primary driver of state and local purchasing activity, though the code may appear incidentally within larger multi-drug cooperative purchasing frameworks.